Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Licensed H5n1 Vaccine

Research Leaders

11 sponsors active, led by Defense Advanced Research Projects Agency

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

4Total
Phase 1 (3)
Phase 4 (1)

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT00755703Phase 1CompletedPrimary

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

NCT03701061Phase 4CompletedPrimary

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

NCT02171819Phase 1CompletedPrimary

Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

NCT01657929Phase 1CompletedPrimary

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Showing all 4 trials

Research Network

Common Treatments

  • Licensed H5n1 Vaccine1
  • Seasonal Influenza Vaccine1
  • Ivacfluah5n1 15 Mcg1
  • H5vlp Alone1
  • Pandemic Influenza Vaccine1

Active Sponsors

  • Defense Advanced Research Projects Agency1
  • Medicago1
  • World Health Organization1
  • Institute of Vaccines and Medical Biologicals, Vietnam1
  • National Institute of Allergy and Infectious Diseases (NIAID)1

Top Investigators

Activity Timeline